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Abstract: 
Apoptosis is the genetically encoded pathway that results in programmed cell death. Apoptosis 
occurs in response to stimuli including cellular stress and DNA damage. Different cell types have 
different thresholds to undergo apoptosis. For example, undifferentiated human embryonic stem cells 
(hESCs) are extremely sensitive to apoptotic stimuli, while neurons are highly resistant. In most cell 
types, apoptotic stimuli result in the activation of the pro-apoptotic protein BAX. Typically, inactive BAX 
is found in the cytosol and translocates to the mitochondria when the cell encounters an apoptotic 
stimulus. At the mitochondria, BAX activates the cascade of events that leads to cell death. We 
previously showed that in hESCs, BAX exists in a constitutively active conformation at the Golgi 
apparatus, which increases the vulnerability of hESCs to apoptotic stimuli. This finding encouraged us to 
investigate the changes in the other key apoptotic factors as cells differentiate from a sensitive hESC state 
to a resistant neuron state. To do so, hESCs were differentiated into neurons (nociceptors) using the 
Struder protocol. Immunofluorescence and quantitative real time PCR verified that the differentiation into 
nociceptor neurons was successful. Changes in gene expression levels of various genes involved in the 
cell death pathway provide understanding into the dynamic mechanisms by which distinct thresholds for 
apoptosis may be reached for different cell types upon differentiation. 
Additionally, we were interested in investigating the changes of BAX activation during 
development. Specifically, we wished to use a mouse model where the endogenous mouse BAX (mBAX) 
gene is replaced with a functional GFP tagged mBAX gene, to study BAX activation during development. 
In order to do so, it was necessary to first make a construct with GFP tagged mBAX and check its 
translocation and function in a mouse cell line. This was done by cloning the mBAX gene downstream of 
GFP and transfecting the resulting plasmid into wild-type and BAX/BAK double knockout mouse 
embryonic fibroblasts (MEFs). Expression and function of mBAX was verified using etoposide 
treatments, determining cell death percentages, and immunofluorescence of active BAX. Our results 
convincingly showed that GFP tagged mBAX was functional in mouse cells. Future work will include 
generating a mouse with GFP tagged BAX to continue investigating the dynamic changes in BAX 
activation during development.   
 
Introduction: 
Apoptosis is a type of cellular death by which an organism is able to get rid of unwanted and 
damaged cells in the body. Apoptosis is implicated in numerous biological processes from embryogenesis 
to aging, from normal tissue homeostasis to many human diseases. Different cell types respond uniquely 
to various apoptotic stimuli, such as DNA damage or ER stress, depending on their thresholds to different 
apoptotic stimuli.  For instance, postmitotic neurons are highly resistant to apoptosis. This resistance is 
essential for the long term survival of postmitotic neurons and for their physiological requirements, as 
they do not divide and must last for the organism’s entire life. The consequences of neuron degeneration 
due to apoptosis gone awry can be seen in diseases such as Alzheimer’s. On the other end, embryonic 
stem cells are extremely sensitive to apoptosis. This sensitivity is essential in an organism’s early stages 
of development, as there is a dire need to eliminate the passing of DNA damage to later cell generations 
of the embryo.  The mechanisms underlying different thresholds of different cells to apoptosis is not well 
understood and is of significant interest. 
BAX, a pro-apoptotic protein, plays a very crucial role in apoptosis. 
Typically, BAX is present in an inactivated form in the cytosol of most cells. 
When the cell encounters an apoptotic trigger, BAX becomes activated and is 
translocated to the mitochondria where it initiates a cascade of events that 
leads to cellular death. The Deshmukh lab is interested in studying the various 
mechanisms underlying cellular death in human embryonic stem cells and 
neurons. Specifically, we are interested in studying the differences that 
allow human embryonic stem cells (hESCs) to be extremely sensitive 
on one end of the spectrum, and neurons to be highly resistant on the 
other. Interestingly, a study published in the Deshmukh Lab by Dumitru et al. (1) convincingly illustrated 
a mechanism responsible for the higher sensitivity of hESCs to apoptosis. 
The study showed presence of constitutively active BAX protein located in 
the Golgi apparatus in hESCs, as seen in Figure 1. Maintenance of the 
active state allows these undifferentiated cells to initiate apoptosis readily. 
Figure 2 (2) is a diagram presented previously by the Deshmukh lab that 
shows BAX in undifferentiated hESCs versus differentiated hESCs. Within 
two days of differentiation, cells become comparatively resistant to cell 
death and no longer express active BAX. Knockdown of BAX and 
subsequent loss of BAX at the Golgi apparatus made the cells resistant to 
cell death, which further confirmed the hypothesis (2).  
With knowledge of this background, a project arose with two 
distinct goals, the first of which is discussed here. The first goal of this 
Figure 1: Immunofluorescence 
showing that active BAX (BAX 
6A7) is present at the Golgi in 
undifferentiated hESCs (1)  
Figure 2: Representation of 
activated BAX in hESCs, attributing 
to their increased sensitivity to 
apoptotic stimuli  
project aimed to investigate the dynamic changes in expression levels of various apoptotic proteins as 
hESCs became differentiated to neurons.  Furthermore, we were interested in discovering the long-term 
apoptotic machinery changes during the process of differentiation that allow a cell to go from an 
extremely sensitive hESC state to a highly resistant neuron state. An in depth knowledge of the 
mechanisms regulating thresholds of different cells to apoptosis would allow for a better understanding of 
disease conditions such as neurodegenerative diseases or cancers where the process of apoptosis is 
dysregulated. A panel of genes was selected to investigate the dynamic changes occurring with the 
differentiation of hESCs to neurons. The genes can be broadly divided into four categories: (1) pro-
apoptotic proteins, (2) anti-apoptotic proteins, (3) pluripotency markers, and (4) neuronal differentiation 
markers. Expression patterns of pluripotency markers and differentiation markers would ensure a 
successful differentiation process. Classically, we would expect downregulation of pluripotency markers 
and an upregulation of differentiation markers with the progress of differentiation. Additionally, 
monitoring a range of cell death markers (pro-apoptotic proteins and anti-apoptotic proteins) would help 
to discover the key players in the apoptotic process in cells at different stages of differentiation. Genes 
investigated are listed in Table 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Category Gene Role 
Pro-apoptotic BAX BCL2 family/ multi domain effectors 
BAK 
Anti-apoptotic BCL2 BCL2 family 
BCL-XL 
Pluripotency Markers OCT4 General pluripotency marker 
NANOG 
KLF4 
SOX2 Indicates neuronal stem cell identity 
Neuronal Differentiation Markers TUJ1 General neuronal marker 
BRN3A Sensory neuron marker 
ISLET1 
VGLUT2 Nociceptor marker 
TAC1 
Table 1: Four categories of genes investigated, the respective genes belonging in each category, and the role of each 
individual gene 
 
Embryonic stem cells are an outstanding model to investigate these changes, as you can induce 
their differentiation into neurons and see the changes occurring as these cells mature. Embryonic stem 
cells have yet to be studied to see how the machinery of the apoptotic pathway changes as differentiation 
occurs. Equally important, the biology of the apoptotic pathways has yet to be studied in human neurons 
differentiated from hESCs, which was a part of this project’s goal. 
 To study the changes in the apoptotic machinery during the differentiation of hESCs to neurons, 
hESCs (H9) were specifically differentiated into nociceptive neurons and samples were collected at 
various stages of differentiation to track the changes that make hESCs sensitive to cell death and neurons 
resistant to cell death. Three independent experiments were performed - biological replicates (BR1, BR2 
and BR3). The differentiation protocol used was adopted from a study published by Lorenz Struder Lab 
in 2012, “Combined small molecule inhibition accelerates developmental timing and converts human 
pluripotent stem cells into nociceptors” (3). The method uses a combination of small molecules that 
regulate different pathways to drive human pluripotent stem cell differentiation to nociceptors. One of the 
greatest advantages of this protocol is the quickened rate at which nociceptors can be formed. This 
differentiation protocol uses five different small molecules that regulate different pathways. These 
inhibitors are listed in Table 2. 
Small Molecule  Pathway Inhibited 
LDN193189 Bone morphogenetic protein (BMP) inhibitor - replaces Noggin for neuralization  
SB431542 TGF-β / SMAD inhibitor 
CHIR99021 GSK-3β inhibitor 
SU5402 VEGFR2, FGFR1, PDGFRβ and EGFR inhibitor 
DAPT g-Secretase inhibitor 
Table 2: Small molecule inhibitors used during the differentiation protocol and the respective pathways they inhibit 
The first two inhibitors in Table 2 are together termed as LSB.  The last three inhibitors are 
termed together as 3i. Together, LSB3i inhibition has shown to induce pluripotent hESCs into neurons. 
Specifically, the 3i inhibitors initiate nociceptor differentiation.  Furthermore, these neurons were seen to 
be sensory neurons, and most specifically, they were categorized as nociceptors.  
During the progression of the differentiation protocol, cells were fixed for immunofluorescence 
on days 0, 15 and 30.  Gene expression with real time PCR (qRTPCR) was measured for days 0, 2, 4, 6, 
10 and 15 samples. 
The second aim of this project arose after the Deshmukh lab discovered the presence of 
constitutively activated BAX in hESCs, as seen in Figure 1 discussed above (1). The Deshmukh lab 
became interested in identifying the status of BAX at various stages of development. To accomplish this, 
we are interested in creating a mouse model system where the endogenous mBAX gene is tagged to GFP 
protein. Before making a mouse model, it was essential to make a construct with a GFP tagged mBAX 
gene and check the GFP tagged BAX activation, translocation to the mitochondria, and function in a 
mouse cell line. This was accomplished by cloning mBAX gene in a GFP vector and checking the 
activation, translocation and function of the resultant mBAX-GFP protein in BAX/BAK double knockout 
cells.  
 
Methods: 
Methods for the first portion of the project - differentiation of hESCs into neurons and analysis of 
dynamic changes: 
(1) Differentiation of hESCs into neurons: 
Differentiation was accomplished using the protocol mentioned above from the Lorenz Struder 
Lab (3). Cells were plated as single cells using Accutase as per manufacturer’s protocol. Once cells were 
70%-80% confluent, neural differentiation was initiated. Medium made is seen in Table 3. KSR 
(knockout serum replacement) medium consisted of 820 mL of Knockout DMEM, 150 mL Knockout 
Serum Replacement, 1 mM L-Glutamine, 100 µM MEM nonessential amino acids, and 0.1 mM β-
mercapotoethanol (3). LSB (consisting of the 100 nM of LDN193189 and 100 µM SB431542) was added 
starting at day 0 through day 5 (3). Cells were fed every 24 hours. N2 medium was given to cells in 
increasing 25% increments every other day beginning on day 4 (day 4 with 25%, day 6 with 50% N2, day 
8 with 75% N2 and day 10 with 100% N2) (3). 3i inhibitors (3 µM CHIR99021, 10 µM SU5402, and 10 
µM DAPT) were added starting on day 2 through day 10 (3). This protocol was used for BR1, BR2 and 
BR3 alike.  
 
 
 
Media Components Days Delivered 
M1 Medium KSR media 
LDN193189 (100 nM) 
SB431542 (100 µM) 
Day 0, 1 
M2 Medium KSR media 
LDN193189 (100 nM) 
SB431542 (100 µM) 
CHIR99021 (3µM) 
SU5402 (10 µM) 
DAPT (10 µM) 
Day 2, 3 
N2-25 Medium KSR media (75%) 
N2 media (25%) 
LDN193189 (100 nM) 
SB431542 (100 µM) 
CHIR99021 (3µM) 
SU5402 (10 µM) 
DAPT (10 µM) 
Day 4, 5 
N2-50 Medium KSR media (50%) 
N2 media (50%) 
LDN193189 (100 nM) 
SB431542 (100 µM) 
CHIR99021 (3µM) 
SU5402 (10 µM) 
DAPT (10 µM) 
Day 6, 7 
N2-75 Medium KSR media (25%) 
N2 media (75%) 
LDN193189 (100 nM) 
SB431542 (100 µM) 
CHIR99021 (3µM) 
SU5402 (10 µM) 
DAPT (10 µM) 
Day 8, 9 
N2-100 Medium N2 media (100%) 
NGF (25 ng/ml) 
BDNF (25 ng/ml) 
GDNF (25 ng/ml) 
Day 10-30 
Table 3: Medium names, components and days delivered throughout the differentiation protocol 
 
As seen in the table, no inhibitors were given after day 10. Cells were split on day 10. 
Approximately 1,000,000 cells were seeded per well of a 6-well plate. These cells were fed as described 
in Table 3.  
(2) Immunofluorescence:  
Cells fixed on days 0, 15 and 30 for immunofluorescence were stained to see the following neuronal 
markers: TUJ1 (a general neuronal marker), BRN3A and ISLET1 (both sensory neuronal markers). TUJ1 
primary antibody (Cell Signaling) was diluted in a 1:200 ratio, BRN3A primary antibody (Abcam) was 
diluted in a 1:200 ratio, and ISLET1 primary antibody (Abcam) was diluted in a 2 µg/mL ratio. 
(3) RNA analysis: 
Total RNA was isolated from samples in a three step process using TRI reagent, as per 
manufacturer’s protocol. First, TRI Reagent is used to lyse cells and create a homogenous lysate. Secondly, 
phase separation was initiated by adding chloroform. The uppermost aqueous layer, containing the RNA, 
was extracted and isopropanol was added to this extracted layer in order to precipitate the RNA.  After 
RNA was processed, it was run on a 1% agarose gel to assess the integrity of the total RNA. Isolation of 
intact RNA is essential for the downstream gene expression assays. 
After RNA integrity was ensured by evaluating the agarose gel as well as by taking each sample’s 
absorbance measurement with a NanoDrop instrument. This instrument provided a 260/280 ratio - a ratio 
of absorbance at 260 nm and 280 nm in order to assess the purity of nucleic acids.  According to Thermo 
Scientific, a ratio of ~2.0 is accepted as “pure” for RNA samples. A 260/280 ratio lower than ~2.0 indicates 
the presence of phenolic compounds or protein contamination, which can affect downstream gene assays. 
Another ratio, 260/230 - a ratio of absorbance at 260 nm and 230 nm - was used as a secondary measure to 
assess the purity of nucleic acids. A 260/230 ratio around ~2.2-2.0 indicates a “pure” RNA sample. A 
260/230 ratio lower than this range may indicate contamination of compounds that absorb around 230 nm. 
After ensuring that samples were considered pure, cDNA was made from all of the RNA samples in order 
to eventually complete a gene analysis with the genes listed in Table 1. Additionally, cDNA was made from 
a WT hESC line - WA09 - in order to ensure that primers for each gene were working. cDNA was 
synthesized as per manufacturer’s protocol using Applied Biosystem’s “High-capacity cDNA reverse 
transcription kit”. 
Once cDNA was synthesized, qRTPCR was utilized to measure gene expression levels in various 
samples. Primers were quality confirmed by using a WT cDNA from human stem cells and once the quality 
was confirmed, the primers were used for forward analysis. This verification allowed for further use of the 
certain primers on days 0, 2, 4, 6, 10 15 samples.  The genes tested were: BAX, BAK, BCL2, BCL-XL, 
OCT4, NANOG, KFL4, SOX2, TUJ1, ISLET1, VGLUT2, TAC1, and and a primer table is seen in Table 
4.  
 
Oligo Name Forward Sequence (5’-3’) Reverse Sequence (5’-3’) 
BAX CAAACTGGTGCTCAAGG CCAACCACCCTGGTCTTGG 
 CCCGAGAGGTCTTTTTCCGAG CCAGCCCATGATGGTTCTGAT 
BAK GCCACCAGCCTGTTTGAG CTGCCACCCAGCCACCC 
 ATGGTCACCTTACCTCTGCAA TCATAGCGTCGGTTGATGTCG 
BCL2 GCGACGACTTCTCCCGC GCGATGTTGTCCACCAGG 
BCL-XL GTAGTGAATGAACTCTTCCG GTATCCCAGCCGCCGTTCTC 
OCT3/4 GGAAGGAATTGGGAACACAAAGG AACTTCACCTTCCCTCCAACCA 
NANOG CCTGTGATTTGTGGGCCTG GACAGTCTCCGTGTGAGGCAT 
KLF4 ACAGTCTGTTATGCACTGTGGTTTCA CATTTGTTCTGCTTAAGGCATACTTGG 
SOX2 TGGCGAACCATCTCTGTGGT CCAACGGTGTCAACCTGCAT 
TUJ1 GTATCCCGACCGCATCAT TCTCATCCGTGTTCTCCA 
ISLET1 GCAGAGTGACATAGATCAGCCTG GCCTCAATAGGACTGGCTACCA 
VGLUT2 GAGAGGAGTAGACTGGCAACCA CTGAAGACCAGCCAGTGTACTG 
TAC1 TTACTGGTCCGACTGGTACGAC CAAAGAACTGCTGAGGCTTGGG 
Table 4: List of forward and reverse primer sequences from Sigma-Aldrich used in qRTPCR  
 
 
Methods for the second portion of the experiment - cloning of mBAX gene into a GFP vector and 
assessment of activation, translocation and function of the resultant mBAX-GFP protein: 
(1) Cloning: 
 The mBAX gene (Addgene Plasmid #8783) was cloned at the C-terminus of GFP gene in the 
pEGFPC1 plasmid (Addgene GenBank Accession #: U55763). This method utilized a single restriction 
enzyme, EcoRI.  After the digestion, the 5’-ends of DNA were dephosphorylated using CIP protocol 
(New England BioLabs).   
The samples were run on an agarose gel and depending on the respective sizes, the DNA bands 
were extracted using QAIgen Gel Purification Columns as per manufacturer’s protocol. This resulted in a 
mBAX gene insert of 600 base pairs and a linearized pEGFPC1 plasmid. Ligation was completed using 
Quick Ligase (New England BioLabs) as per manufacturer’s protocol.  
The ligation product was transformed into Dh5𝛼 competent cells and grown on LB plates and 
incubated overnight at 37°C. 5 random colonies were chosen, streaked on new LB plates to increase the 
bacterial culture. After sufficient growth on the second plate, mini-cultures were done to isolate the 
plasmid. 
Restriction digestion was done again to confirm the insertion of the clone. The clones that showed 
the presence of the mBAX gene insertion were sent for sequencing to confirm that the orientation of 
insertion was correct before transfection. 
(2) Cell Culture: 
 BAX/BAK double knockout (BBDKO) MEFs and wild-type mouse embryonic fibroblasts (WT 
MEFs) were cultured in DMEM high-glucose media. 
(3) Transfection and Treatment: 
 BBDKO MEFs were transfected with the GFP-mBAX plasmid and an empty vector, pEGFPC1, 
using Lipofectamine 3000 transfection reagent (Thermo Fisher Scientific) as per manufacturer’s protocol. 
WT MEFs were used as a positive control. 24 hours after transfection, all cells were treated with 20 µM 
etoposide and DMSO for 24 hrs to assess their apoptotic response to DNA damage.  
(4) Immunofluorescence 
Cells were processed for immunofluorescence 24 hours after treatments. Staining for mBAX-GFP 
was done to ensure that the transfection was successful. BAX 6A7 antibody (Sigma-Aldrich) was also 
used, which detects BAX only in its active conformation (1). Staining for BAX 6A7 allowed us to assess 
if mBAX was able to become activated after transfection. Cell death was quantified for all conditions in 
order to assess whether or not mBAX was functional in initiating the cascade to cellular death. 
 
Results: 
For the first portion of the experiment, results for the qRTPCR analysis can be seen in the 
appendix. Fold changes for the genes over the course of the differentiation protocol are shown. The 
individual graphs include results for all three biological replicates (BR1, BR2, and BR3). The 
pluripotency markers, OCT4, SOX2, KLF4, NANOG, display a general trend of decreasing in fold 
change over the course of the 30-day differentiation protocol.  This is to be expected as hESCs lose their 
pluripotent characteristic when they become differentiated. Exceptions can be seen with SOX2, which 
increases from day 0 to day 2 and then decreases after day 6 and is minimally present by day 15. 
Additionally, KLF4 increases in fold change from day 0 to day 2 and remains relatively steady throughout 
the course of the differentiation protocol. KLF4 fold change on day 10 in BR2 is oddly seen to 
significantly increase to a fold change of approximately 13.   
The neuronal differentiation markers, TUJ1, ISLET1, VGLUT2, and TAC1, increased in fold 
change throughout the differentiation protocol, which is expected as cells begin to express more neuronal 
character. All four genes displayed relatively minimal expression levels from day 0 through day 6. By day 
10, the expression levels increased significantly. For TUJ1 and VGLUT2, these fold changes remained 
relatively steady from day 10 to day 15. ISLET1 continued to increase after day 10 and reached highest 
expression level on day 15 for BR1, BR2 and BR3. TAC1 displayed significantly increased fold change 
from day 6 to day 10, and then decreased in expression by day 15.  
Pro-apoptotic proteins BAX and BAK displayed high expression on day 0. BAX decreased by 
day 2 and even moreso by day 4, but maintained a relatively steady expression level from day 4 through 
day 15. BAK decreased in expression after day 0, was minimally present from day 4 through day 6, and 
then slightly increased on day 10 and increased even more by day 15. The anti-apoptotic proteins, BCL2 
and BCL-XL both maintained a steady expression level from day 0 to day 6 and they both increased 
expression on day 10.  Both BCL2 and BCL-XL displayed highest expression levels on day 15.  
Figure 3 displays an increasing prevalence of TUJ1 and ISLET1 during the process of the 
differentiation protocol. On day 0, TUJ1 and ISLET1 were minimally present. Both TUJ1 and ISLET1 
increased by day 15 and increased moreso by day 30. Figure 4 displays an increasing presence of TUJ1 
and BRN3A during the differentiation protocol. On day 0, TUJ1 and BRN3A were minimally present. 
Their presence increased upon day 15 and even more so upon day 30.  
 
Figure 3: Brightfield and immunofluorescence images of cells on days 0, 15 and 30 with tagged TUJ1 and ISLET1 
genes 
 
 
Figure 4: Brightfield and immunofluorescence images of cells on days 0, 15 and 30 with tagged TUJ1 and BRN3A 
genes 
 
Results for the second portion of the experiment begin with Figure 5. This immunofluorescence 
image shows BBDKO MEFs after transfection with only pEGFPC1 plasmid (left panel) and after 
transfection with mBAX-GFP plasmid (middle and right panels). These cells were untreated and are 
instead healthy and dying cells in a normal culture. This image provides information on the success of the 
transfections as well as details on the location of mBAX-GFP plasmid in healthy cells versus dying cells. 
Healthy cells transfected with mBAX-GFP plasmid are seen in the middle panel and are magnified. These 
healthy cells display mBAX-GFP generalized in the cytosol. Dying cells transfected with mBAX-GFP 
plasmid in the normal untreated culture can be seen in the magnified right panel. These dying cells 
display mBAX-GFP in a punctate pattern at a specific organelle. It can be predicted that this organelle is 
the mitochondria, as it would be expected for mBAX to translocate to the mitochondria to initiate 
apoptosis. 
 
Figure 5: Immunofluorescence images of BBDKO MEFs after transfection with mBAX-GFP. These images display 
a normal untreated culture  
 
 Figure 6 and Table 5 provide information about percentage of cell death of transfected cells after 
treatment with DMSO and 20 µM etoposide. Etoposide is known to cause DNA damage, by which the 
cell responds by initiating the cascade leading to apoptosis (4).  As expected, cell death is higher for cells 
treated with 20 µM etoposide compared to cells treated with DMSO, which was a control. Cell death 
percentage remained relatively constant for each cell type, which was expected. Cell death percentage for 
WT MEFs was highest at 96%, followed by mBAX-GFP transfected BBDKOs at 50%, and lastly 
pEGFPC1 transfected BBDKOs at 20%. 
 
 
Figure 6: Percentage of cell death for WT MEF cells, pEGFPC1 transfected BBDKO MEFs and mBAX-GFP 
transfected BBDKO MEFs after treatments with DMSO (blue) and 20 µM Etoposide (orange) 
 
 
 
 DMSO 20 µM Etoposide 
MEF WT 4% 96% 
BBDKO pEGFPC1 9% 20% 
BBDKO mBAX-GFP 11% 50% 
Table 5:  Quantification of cell death percentages for WT MEF cells, pEGFPC1 transfected BBDKO MEFs and 
mBAX-GFP transfected BBDKO MEFs after treatments with DMSO and 20 µM etoposide  
 
 
Figure 7 shows staining for active BAX, BAX 6A7. The presence of active BAX was very low in 
DMSO treated cells, but was significantly increased in 20 µM etoposide treated cells.  
 
Figure 7: This immunofluorescence shows staining for active BAX (6A7) 24 hours after both DMSO treatment and 
20 µM etoposide 
 
Figures 8 and 9 include staining for mBAX-GFP in addition to BAX 6A7 in order to observe the 
overlap with mBAX-GFP and BAX6A7 24 hours after DMSO (Figure 8) and 20 µM etoposide (Figure 9) 
treatments. While Figure 8 displays an overlap of mBAX-GFP and BAX6A7, the overlap in Figure 9 is 
more prevalent. 
 
Figure 8: Staining of mBAX-GFP (middle column) and BAX 6A7 (right column) after 24 hour DMSO treatment 
 
 
Figure 9: Staining of mBAX-GFP (middle column) and BAX 6A7 (right column) after 24 hour 20 µM etoposide 
treatment 
 
Discussion: 
 The results of the first portion of this experiment indicate that the differentiation of hESCs into 
nociceptor neurons was successful. This can be seen with microscopy images, and is also verified with 
RNA analysis and immunofluorescence. RNA gene analysis experiments yielded results as expected, such 
as down-regulation of pluripotency gene markers and up-regulation of neuronal gene markers as 
differentiation of hESCs into neurons proceeded. OCT4 and NANOG in particular significantly decreased 
after day 0, indicating that these cells were not pluripotent after day 2. The relative maintenance of KLF4 
throughout the differentiation protocol and its presence even on day 15 is not expected and contradicts the 
results for the other pluripotency markers and may need to be studied more in the future. Furthermore, 
increased expression of SOX2 after day 0 is expected as this gene indicates neuronal stem cell identity. 
Cells are expected to begin expressing this gene after differentiation into neurons began. 
 The overall decrease in expression levels of the pro-apoptotic proteins BAX and BAK throughout 
the differentiation align with the knowledge of hESC extreme sensitivity. Having higher levels of these 
proteins at the beginning of the differentiation process would allow these cells to undergo rapid apoptosis 
in the case of exposure to any apoptotic stimuli. On the other hand, the increasing expression levels of the 
anti-apoptotic proteins, BCL2 and BCL-XL, align with the knowledge of neurons being highly resistant. 
Increasing levels of these proteins as cells gain more neuronal characteristics would allow these cells to 
resist apoptosis upon exposure to apoptotic stimuli. 
The RNA analysis of neuronal differentiation markers, TUJ1, VGLUT2, ISLET1 and TAC1 
display increasing levels of all four of these genes during the differentiation process. These results 
together indicate that hESCs have become differentiated into neurons, as all four genes are minimally 
expressed from day 0 through day 6 and as all four increase significantly around day 10. In particular, as 
ISLET1 is a sensory neuron marker, its significant increase in expression level indicates that the 
differentiated neurons are in fact sensory neurons. Additionally, the increased prevalence of VGLUT2 
and TAC1, both of which are nociceptor markers, give evidence that the differentiated cells are 
nociceptive neurons.  
The immunofluorescence images from the first portion of the experiment displayed increasing 
prevalence of TUJ1, BRN3A and ISLET1. These results demonstrated that hESCs contained neuronal 
markers and were sensory neurons in particular, as BRN3A and ISLET1 are sensory neuron markers. 
From the second portion of the experiment, the transfections were successful using both the GFP-
pEGFPC1 empty vector, as well as the mBAX-GFP plasmid. This can be seen by the 
immunofluorescence images in Figure 5, which display green, GFP-tagged cells for both of these 
transfections. This figure also demonstrates the plasmid generalized to the entire cell in healthy cells, 
whereas the plasmid was localized to specific organelles in dying cells that were transfected with mBAX-
GFP plasmid, due to the presence of mBAX in this plasmid. These results demonstrate that the 
transfected mBAX plasmid is able to translocate successfully. Future experiments are needed to verify 
that the mitochondria was indeed the organelle to which mBAX-GFP was localized.  
 Due to BAX being a pro-apoptotic player, its presence in a cell would suggest an increased 
proportion of cell death with treatment of 20 µM etoposide. This is seen visually and quantitatively. After 
treatment with 20 µM etoposide, it would be expected that WT MEFs would have the largest amount of 
cellular death. WT MEFs, with endogenous BAX acting as a pro-apoptotic protein, would initiate the 
cascade of apoptosis and ultimately result in a significant amount of cellular death. This is seen in Figure 
6 and Table 5 with the positive control, WT MEFs, at 96% cell death after treatment with etoposide. 
BBDKO MEFs transfected with only the pEGFPC1 empty vector (negative control) did not contain BAX 
in the cell, and thus it would be expected that these cells would undergo far less cellular death compared 
to WT.  This is seen with a 20% cell death after treatment with etoposide. BBDKO MEFs transfected with 
mBAX-GFP contained BAX and thus cell death was expected to be greater compared to the BBDKO 
MEFs transfected with the pEGFPC1 plasmid only. This was seen with the results. Furthermore, the 
increased cellular death of the mBAX-GFP transfected BBDKO MEFs compared to the pEGFPC1 
plasmid transfected BBDKO MEFs indicates that the BAX protein contained in the plasmid was 
functional and was able to initiate the apoptotic cascade. The decreased cell death in the mBAX-GFP 
transfected BBDKO MEFs compared to the WT MEFs is likely due to the fact that transfection efficiency 
is not 100% and therefore not all of the cells contained BAX identically to the WT. The larger proportion 
of cell death in MEF WT cells compared to the mBAX-GFP transfected MEFS suggests that the 
transfection protocol could be optimized in the future. 
The immunofluorescence images in Figure 9 demonstrates that the same mBAX-GFP plasmid 
that was transfected into the BBDKO MEFs was able to translocate to the mitochondria and was also able 
to become activated. The presence of activated BAX in the control DMSO treatment in Figure 8 is due to 
the fact that DMSO is somewhat toxic to cells, although it is not nearly as toxic as etoposide.  
Together, the results from the second portion of this project confirm that (1) GFP tagged mBAX 
is able to translocate to the mitochondria, (2), GFP tagged mBAX is able to become activated (seen with 
the strong overlap in Figures 8 and 9) and (3), the GFP tagged mBAX is able to initiate the cascade to 
lead to cellular death (seen in Figure 6 and Table 5). With these results, the Deshmukh lab will now be 
able to observe the developmental changes of BAX in apoptosis in a mouse model.    
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Appendix: 
  
	  
Figure 10: OCT4 fold changes for BR1, BR2, and BR3 over the course of the differentiation protocol 
 
	  
Figure 11: NANOG fold changes for BR1, BR2, and BR3 over the course of the differentiation protocol 
	  
	  
Figure 12: KLF4 fold changes for BR1, BR2, and BR3 over the course of the differentiation protocol 
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Figure 13: SOX2 fold changes for BR1, BR2, and BR3 over the course of the differentiation protocol 
 
	  
Figure 14: TUJ1 fold changes for BR1, BR2, and BR3 over the course of the differentiation protocol 
 
	  
	  
Figure 15: VGLUT2 fold changes for BR1, BR2, and BR3 over the course of the differentiation protocol 
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Figure 16: ISLET1 fold changes for BR1, BR2, and BR3 over the course of the differentiation protocol 
 
	  
	  
Figure 17: TAC1 fold changes for BR1, BR2, and BR3 over the course of the differentiation protocol 
	  
	  
Figure 18: BCL2 fold changes for BR1, BR2, and BR3 over the course of the differentiation protocol 
	  
	  
0
2000
4000
6000
8000
10000
DAY  0 DAY  2 DAY  4 DAY  6 DAY  
10
DAY  
15
Fo
ld
  C
ha
ng
e
ISLET1
BR1 BR2 BR3
0
20
40
60
80
DAY  0 DAY  2 DAY  4 DAY  6 DAY  10 DAY  15
Fo
ld
  C
ha
ng
e
TAC1
BR1 BR2 BR3
0
2
4
6
8
10
DAY  0 DAY  2 DAY  4 DAY  6 DAY  10 DAY  15
Fo
ld
  C
ha
ng
e
BCL2
BR1 BR2 BR3
	  
Figure 19: BCL-XL fold changes for BR1 and BR3 over the course of the differentiation protocol 
	  
	  
Figure 20: BAX fold changes for BR1, BR2, and BR3 over the course of the differentiation protocol 
	  
	  
Figure 21: BAK fold changes for BR1, BR2, and BR3 over the course of the differentiation protocol 
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